미국의 조영제 시장 규모, 점유율 및 동향 분석 보고서 : 모달리티별, 유형별, 용도별, 부문별 예측(2023-2030년)

U.S. Contrast Media Market Growth & Trends:

The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth. Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market. Chronic diseases, such as cancer and diabetes, are rapidly becoming a major public health concern and are among the leading causes of death across the U.S., resulting in the need for early diagnostic tools and effective treatment options.

Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth. The COVID-19 outbreak had a negative impact on the market due to decreased patient visits to hospitals. Many radiology departments experienced a rapid decline in imaging case volume. However, many states in the U.S. have begun to reopen their economies; however, it will take time for the utilization rate of contrast media to reach pre-pandemic levels. In addition, with the launch of COVID-19 vaccines and ease in restrictions, the import and export of raw materials have resumed. This, in turn, therefore, is expected to boost the market growth over the forecast period.

U.S. Contrast Media Market Report Highlights:

• Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market
• The iodinated contrast media dominated the market and held the largest market share of over 60% in 2022 on account of excellent radio-opacity and low toxicity of iodinated contrast media than other agents
• The X-ray/CT segment dominated the market and held the largest market share of around 65% in 2022. Wide acceptance and cost-efficiency of X-ray/CT modality boost the adoption of contrast agents for this modality
• The rising demand for imaging procedures has resulted in extensive R&D activities by contrast media manufacturers to launch novel products in the market and to get approved for new indications
• For instance, in 2021, Bracco got the U.S. FDA approval for 20-vial pack configuration of Lumason, which is an ultrasound contrast media agent

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Modality
  • 1.1.3. Application
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Modality outlook
  • 2.2.3. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Contrast Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. U.S. Contrast Media Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. U.S. Contrast Media: Type Estimates & Trend Analysis

• 4.1. U.S. Contrast Media Market, By Type Key Takeaways
• 4.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Microbubble Contrast Media
  • 4.3.1. Microbubble contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Gadolinium-based Contrast Media
  • 4.4.1. Gadolinium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Iodinated Contrast Media
  • 4.5.1. Iodinated contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Barium-based Contrast Media
  • 4.6.1. Barium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Contrast Media: Modality Estimates & Trend Analysis

• 5.1. U.S. Contrast Media Market, By Modality Key Takeaways
• 5.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Ultrasound
  • 5.3.1. Ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Magnetic Resonance Imaging (MRI)
  • 5.4.1. Magnetic resonance (MRI) imaging market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. X-RAY/Computed Tomography (CT Scan)
  • 5.5.1. X-RAY/computed tomography (CT Scan) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Contrast Media: Application Estimates & Trend Analysis

• 6.1. U.S. Contrast Media Market, By Application Key Takeaways
• 6.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Cardiovascular
  • 6.3.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Neurological Disorders
  • 6.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Gastrointestinal Disorders
  • 6.5.1. Gastrointestinal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Cancer
  • 6.6.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Nephrological Disorders
  • 6.7.1. Nephrological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Musculoskeletal Disorders
  • 6.8.1. Musculoskeletal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Bayer AG
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. GE Healthcare
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Guerbet
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Lantheus Medical Imaging, Inc
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Bracco Diagnostic Inc
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Trivitron Healthcare
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Nano Therapeutics Pvt Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. IMAX Diagnostic Imaging
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. CMC Contrast AB (ASCELIA PHARMA AB)
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives